Findings from Analysis Group Inc. Provides New Data on Non-Small Cell Lung Cancer (Real-world Safety of First-line Immuno-oncology Combination Therapies for Advanced Non-small-cell Lung Cancer).

A recent study conducted by Analysis Group Inc. examined the real-world safety of first-line immuno-oncology combination therapies for advanced non-small cell lung cancer (NSCLC). The study analyzed data from a de-identified database of patients with advanced NSCLC who were treated with different combination therapies. The most common adverse events reported were fatigue, pain, dyspnea, weight loss, decreased appetite, diarrhea, nausea/vomiting, cough, constipation, and rash. The study found that the safety experiences of patients treated with the immuno-oncology combination therapies were generally similar across different treatment groups. These findings suggest that these therapies have similar safety profiles when used as a first treatment for NSCLC that has spread or come back. [Extracted from the article]